CUSIP: 29428V104
What is CUSIP 29428V104?
CUSIP 29428V104 identifies EPZM - EPIZYME INC - COM in SEC 13F datasets.
Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.
Open recent reporting periods for CUSIP 29428V104:
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2022 Q4 | 0 | $0 | -$4,000 | 0 | |
| 2022 Q3 | 218,384 | $4,000 | -$186,861,294 | $0.02 | 1 |
| 2022 Q2 | 127,185,873 | $186,959,424 | -$19,845,585 | $1.47 | 86 |
| 2022 Q1 | 112,797,515 | $129,726,194 | +$35,356,395 | $1.15 | 113 |
| 2021 Q4 | 84,779,726 | $212,062,772 | -$18,895,269 | $2.50 | 127 |
| 2021 Q3 | 93,676,680 | $479,803,021 | -$19,984,727 | $5.12 | 113 |
| 2021 Q2 | 95,093,300 | $790,193,183 | -$4,176,287 | $8.31 | 125 |
| 2021 Q1 | 95,499,733 | $831,798,028 | -$7,992,634 | $8.71 | 132 |
| 2020 Q4 | 98,990,884 | $1,075,076,271 | -$6,741,917 | $10.86 | 135 |
| 2020 Q3 | 92,482,999 | $1,103,347,621 | -$37,302,709 | $11.93 | 149 |
| 2020 Q2 | 93,611,465 | $1,503,407,182 | +$17,627,121 | $16.06 | 157 |
| 2020 Q1 | 92,587,438 | $1,434,786,931 | +$1,885,890 | $15.51 | 138 |
| 2019 Q4 | 91,671,282 | $2,254,566,079 | +$217,606,177 | $24.60 | 129 |
| 2019 Q3 | 80,322,119 | $828,478,298 | +$904,470 | $10.32 | 107 |
| 2019 Q2 | 79,751,952 | $1,000,590,266 | +$27,096,141 | $12.55 | 127 |
| 2019 Q1 | 77,877,065 | $964,818,171 | +$158,642,546 | $12.39 | 118 |
| 2018 Q4 | 66,167,639 | $407,489,432 | +$27,509,544 | $6.16 | 102 |
| 2018 Q3 | 59,225,232 | $627,861,034 | -$10,751,160 | $10.60 | 102 |
| 2018 Q2 | 59,953,813 | $812,338,254 | -$9,764,590 | $13.55 | 105 |
| 2018 Q1 | 59,961,145 | $1,064,294,942 | +$11,851,257 | $17.75 | 106 |
| 2017 Q4 | 59,637,657 | $748,517,414 | -$17,861,931 | $12.55 | 99 |
| 2017 Q3 | 60,366,538 | $1,149,829,008 | +$202,581,167 | $19.05 | 104 |
| 2017 Q2 | 50,134,198 | $757,040,570 | +$30,323,261 | $15.10 | 107 |
| 2017 Q1 | 47,990,313 | $823,022,296 | +$52,529,928 | $17.15 | 95 |
| 2016 Q4 | 48,698,461 | $589,257,005 | +$24,741,791 | $12.10 | 92 |
| 2016 Q3 | 46,723,281 | $459,519,996 | -$6,166,037 | $9.84 | 96 |
| 2016 Q2 | 47,308,257 | $484,441,962 | +$11,518,974 | $10.24 | 96 |
| 2016 Q1 | 46,126,532 | $558,995,000 | +$146,810,642 | $12.12 | 90 |
| 2015 Q4 | 33,915,214 | $543,336,589 | -$41,000,036 | $16.02 | 88 |
| 2015 Q3 | 36,165,256 | $465,071,938 | +$10,555,783 | $12.86 | 96 |
| 2015 Q2 | 34,359,974 | $824,579,536 | +$79,050,851 | $24.00 | 94 |
| 2015 Q1 | 29,419,950 | $552,530,869 | +$151,147,352 | $18.78 | 100 |
| 2014 Q4 | 23,721,769 | $447,608,323 | -$17,196,418 | $18.87 | 82 |
| 2014 Q3 | 23,564,833 | $638,840,183 | +$29,164,119 | $27.11 | 94 |
| 2014 Q2 | 22,451,487 | $698,701,484 | +$31,508,744 | $31.12 | 82 |
| 2014 Q1 | 21,688,805 | $493,848,845 | +$137,623,005 | $22.77 | 73 |